2007
DOI: 10.1159/000102570
|View full text |Cite
|
Sign up to set email alerts
|

A Placebo-Controlled Double-Blind Randomized Study of Venlafaxine in the Treatment of Depression in Dementia

Abstract: Background/Aims: To evaluate the efficacy and safety of venlafaxine in the treatment of major depression in dementia. Methods: Thirty-one outpatients who had dementia and major depression participated in this randomized, double-blind, placebo-controlled, 6-week, flexible dose clinical trial. The screening measures were Cornell Scale for depression in dementia, DSM-IV for depression and dementia and Mini-Mental State Examination. The outcome measures were response rate, Montgomery-Åsberg Depression Rating scale… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
47
0
2

Year Published

2008
2008
2018
2018

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 63 publications
(49 citation statements)
references
References 54 publications
0
47
0
2
Order By: Relevance
“…Studies reviewed previously (39)(40)(41)(42)(43)(44) found that depressed patients with executive dysfunction or Alzheimer's dementia are less responsive to antidepressants. However, in the placebocontrolled trials of antidepressants in depressed patients with Alzheimer's disease, only two of the nine trials studied limited patient selection to moderately severe depression (mean HAM-D score .20 or equivalent MADRS score) (62,63), and in the two largest trials (40,64), about three-quarters of the patients had late-onset depression (P. Rosenberg and S. Banerjee, personal communication, 2011). The effectiveness of antidepressants in Alzheimer's patients who are similar to the drugresponsive subgroup identified in this report (those with a long illness duration and at least moderate depression severity) has not been explored.…”
Section: Discussionmentioning
confidence: 99%
“…Studies reviewed previously (39)(40)(41)(42)(43)(44) found that depressed patients with executive dysfunction or Alzheimer's dementia are less responsive to antidepressants. However, in the placebocontrolled trials of antidepressants in depressed patients with Alzheimer's disease, only two of the nine trials studied limited patient selection to moderately severe depression (mean HAM-D score .20 or equivalent MADRS score) (62,63), and in the two largest trials (40,64), about three-quarters of the patients had late-onset depression (P. Rosenberg and S. Banerjee, personal communication, 2011). The effectiveness of antidepressants in Alzheimer's patients who are similar to the drugresponsive subgroup identified in this report (those with a long illness duration and at least moderate depression severity) has not been explored.…”
Section: Discussionmentioning
confidence: 99%
“…31 The authors found no significant difference in efficacy between the groups, but also no significant difference in reports of adverse events. There are very few randomised controlled trials on the use of antidepressants in dementia (and no other trials using venlafaxine specifically).…”
Section: S E R O To N I N a N D N O R A D R E N A L I N E Reuptake Inmentioning
confidence: 88%
“…SNRIs: Two clinical trials showed that the SNRI venlafaxine in aged depressed patients with/without dementia had no effects on depression-related symptoms (de Vasconcelos Cunha et al, 2007;Schatzberg and Roose, 2006). On the other hand, a recent 8-week clinical showed that the SNRI duloxetine separated significantly from placebo and was well tolerated (Katona et al, 2012).…”
Section: Clinical Insightsmentioning
confidence: 99%
“…Interestingly, in this trial, depressed elderly patients displayed a more severe degree of depression (HAMD >28) than in the two previous trials. In contrast to the trial conducted by Katona and colleagues (Katona et al, 2012), the study undertaken by de Vasconcelos Cunha et al (2007) included depressed elderly patients with mild to moderate dementia with a Mini Mental State Examination score between 10 and 24.…”
Section: Clinical Insightsmentioning
confidence: 99%